Acta Scientific Pharmacology

Short Communication Volume 1 Issue 8

COVID-19; Pharmacological Approaches for Infection Prevention: Old and the New

Gundu HR Rao*

Emeritus Professor, Laboratory Medicine and Pathology, Director, Thrombosis Research, Lillehei Heart Institute, University of Minnesota, USA

*Corresponding Author: Gundu HR Rao, Emeritus Professor, Laboratory Medicine and Pathology, Director, Thrombosis Research, Lillehei Heart Institute, University of Minnesota, USA.

Received: June 01, 2020; Published: July 31, 2020


Severe acute respiratory virus syndrome causing virus, coronavirus 2019 (SARS CoV-2), has caused unprecedented health and economic crisis worldwide. Coronavirus disease (COVDO-19), has caused more death in the USA in the last hundred days, than the wars that the US has fought in this century. It has exceeded, the annual death records of last several decades, by the influenza virus. The genome size of this virus ranges between 27 and 34 kilobases, larger than most other RNA viruses.



  1. Korber B., et al. “Spike mutation pipeline reveals the emergence of a more transmissible form of SARS-CoV-2”. bioRxiv (2020).
  2. Novokmet M., et al. “Understanding Glycans in COVID-19 Drug Design”. Genetic Engineering and Biotechnology News April 1st, (2020).
  3. Mehta N and Alter G. “Opportunities to exploit antibody glycosylation in vaccination”. Future Virology 12 (2017): 325-328.
  4. Ciaglia E., et al. “COVID-19 infection and circulating ACE2 levels: Protective Role in Women and Children”. Frontiers in Pediatrics (2020).
  5. Xu H., et al. “High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa”. International Journal of Oral Science (2020) 12.
  6. Sungnak W., et al. “Nasal epithelia cells together with innate immune genes”. Nature Medicine 26 (2020): 681-687.
  7. Kuba K., et al. “A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus induced lung injury”. Nature Medicine 11 (2005): 8779.
  8. Wang Li., et al. “Hydroxychloroquine-inhibited dengue virus is associated with host defense machinery”. Journal of Interferon and Cytokine Research3 (2015): 143-156.
  9. Savarino A., et al. “Anti- HIV effects of Chloroquine: Mechanisms of inhibition and spectrum of activity”. AIDS 15 (19): 2221-2229, 2001.
  10. Savarino A., et al. “Effects of chloroquine on viral infections: an old drug against today’s diseases”. Lancet Infection Disease11 (2003): 722-727.
  11. Vardanyan RS and Hruby VJ. “Drugs for treating protozoan infections. In: Synthesis of Essential Drugs”. (Authors: Vardanyan and Hruby) (2006): 559-582.
  12. Muraleedharan KM and Avery MA. “Therapeutic Areas 11: Cancer, Infectious Disease, Inflammation and Immunology and Dermatology”. In: Comprehensive Medicinal Chemistry 11, 2007 (Ed; Taylor JB, Triggle DJ) Elsevier Ltd.
  13. Gautret P., et al. “Hydroxychloroquine and azithromycin as a treatment of COVD-19: results of an open-label non-randomized clinical trial”. The International Journal of Antimicrobial Agents (2020).
  14. Vincent MJ., et al. “Chloroquine is a potent inhibitor of SARS coronavirus infection and spread”. Virology Journal 2 (2005): 69.
  15. Tripathy S., et al. “A review on possible modes of action of Chloroquine/Hydroxychloroquine: Repurposing against SAR CoV-2 (COVID-19) pandemic”. The International Journal of Antimicrobial Agents (2020): 106028.
  16. Mehra MR., et al. “Hydroxychloroquine or Chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis”. Lancet (2020).
  17. Lederberg J. “Infectious history”. Science 5464 (2000): 287-293.
  18. Wang M., et al. “Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro”. Cell Research 30 (2020): 269-271.
  19. Elgundi Z., et al. “The State-of-play and future of antibody therapeutics”. Advanced Drug Delivery Reviews 122 (2017): 2-19.
  20. Biegel JH., et al. “Remdesivir for the treatment of Covid-19-Preliminary Report”. The New England Journal of Medicine (2020).
  21. Yu J., et al. “DNA vaccine protection against SARS CoV-2 in rhesus macaques”. Science (2020): Eabc6284.
  22. Zhu F., et al. “Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-labeled, non-randomized, first-in-human trial”. Lancet (2020).
  23. Trogen B., et al. “Adverse consequences of rushing a SASAT CoV-2 vaccine”. JAMA, Viewpoint; COVID-19: Beyond Tomorrow. May 26 (2020).


Citation: Gundu HR Rao. “COVID-19; Pharmacological Approaches for Infection Prevention: Old and the New".Acta Scientific Pharmacology 1.8 (2020): 33-37.


Acceptance rate36%
Acceptance to publication20-30 days

Indexed In

News and Events

  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is July 10, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue"
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.

Contact US